Follicular lymphoma

Overview

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in Western countries, accounting for approximately 20% to 30% of all NHL diagnoses. It is a malignancy of B-lymphocytes (a type of white blood cell) that typically follows an indolent (slow-growing) clinical course. While currently considered incurable with standard chemoimmunotherapy in advanced stages, it is highly manageable, and many patients live for decades with a good quality of life. Recent therapeutic advances, including targeted agents and cellular therapies, are rapidly shifting the treatment paradigm toward deeper remissions and potential functional cures for specific subsets of patients.

This article provides a detailed, structured overview of the disease, covering pathophysiology, clinical presentation, diagnostic workup, staging, risk stratification, treatment algorithms, follow-up care, and emerging therapies.

1. What Is Follicular Lymphoma? (Pathophysiology & Biology)

Cellular Origin

FL arises from germinal center B-cells—specifically, centrocytes (small cleaved cells) and centroblasts (large non-cleaved cells). In a healthy lymph node, the germinal center is the site where B-cells undergo somatic hypermutation and class-switch recombination to produce high-affinity antibodies. FL cells retain this germinal center phenotype, typically expressing CD10, BCL6, and BCL2.

The Hallmark Genetic Lesion: t(14;18)

Over 85% of FL cases harbor the t(14;18)(q32;q21) translocation. This chromosomal rearrangement juxtaposes the BCL2 gene on chromosome 18 next to the immunoglobulin heavy chain (IGH) enhancer on chromosome 14.

• Consequence: Dysregulated, constitutive overexpression of the BCL2 protein.
• Mechanism: BCL2 is an anti-apoptotic protein. Its overexpression prevents programmed cell death (apoptosis), allowing the malignant B-cells to survive indefinitely and accumulate in lymphoid tissues.

Additional Genetic Drivers

While t(14;18) is the initiating event, disease progression and clinical heterogeneity are driven by secondary mutations. Common co-occurring mutations involve:

• Epigenetic modifiers: KMT2D (MLL2), CREBBP, EZH2, EP300.
• Signal transduction: TNFRSF14, RRAGC.
• Cell cycle regulation: TP53 (associated with transformation/high-risk disease).

The Tumor Microenvironment

FL is not just a collection of malignant cells; it is an organ-like structure. The tumor microenvironment (TME)—comprising T-cells (follicular helper T-cells, T-regulatory cells), macrophages, dendritic cells, and stromal cells—plays a critical role in tumor survival, immune evasion, and response to therapy. The composition of the TME is a powerful prognostic factor (e.g., high T-cell infiltration correlates with better outcomes).

2. Epidemiology and Risk Factors

3. How Does It Look? (Pathology, Imaging & Gross Appearance)

This section details the visual and microscopic characteristics of the disease, essential for understanding the diagnosis.

Gross Pathology (Naked Eye Appearance)

• Lymph Nodes: Typically enlarged, discrete, rubbery, and non-tender. On cross-section, the cut surface is usually pale tan to white, bulging, and homogenous (“fish-flesh” appearance). They lack the necrosis or hemorrhage often seen in aggressive lymphomas.
• Spleen: Frequently enlarged (splenomegaly). The capsule may be thickened. Cut surface shows multiple, small, pale military nodules (1–3 mm) or diffuse white pulp expansion.
• Bone Marrow: Often involved (40–70% at diagnosis). Grossly, the marrow may appear pale or show focal pale nodules.
• Extranodal Sites: Rare at diagnosis (<15%). When present, the gastrointestinal tract (duodenum, small bowel) is the most common site, appearing as multiple polyps or diffuse mucosal thickening (“lymphomatous polyposis”).

Microscopic Appearance (Histology – H&E Staining)

The diagnosis rests on architecture and cytology.

A. Architectural Patterns:

1. Nodular (Follicular) Pattern (Majority): Neoplastic follicles are closely packed, back-to-back, distorting normal nodal architecture. They lack the “starry sky” macrophages (tingible body macrophages) seen in reactive germinal centers. Polarization (light zone/dark zone distinction) is lost.
2. Diffuse Pattern: Areas where follicular structure is effaced. Significance: Large diffuse areas may indicate Grade 3B or transformation to Diffuse Large B-Cell Lymphoma (DLBCL).

B. Cytology (The Centrocytes vs. Centroblasts Balance):

• Centrocytes (Small Cleaved Cells): Small nuclei, scant cytoplasm, irregular nuclear contours (cleaved, folded, “cerebriform”). These are the hallmark cells.
• Centroblasts (Large Non-Cleaved Cells): Larger nuclei (2x a red blood cell), open chromatin, prominent nucleoli, moderate cytoplasm.

C. Grading System (WHO Classification):

Grading is based on the number of centroblasts per high-power field (HPF; 40x objective, 0.159 mm²) averaged over 10 neoplastic follicles.

Critical Note:** Grade 3B is biologically and clinically distinct from Grades 1–3A. It lacks the t(14;18) in many cases and behaves like DLBCL.

Immunophenotype (Immunohistochemistry / Flow Cytometry)

This confirms the B-cell lineage and germinal center origin.

Imaging Appearance (Radiology)

• CT Scan (Neck/Chest/Abdomen/Pelvis):
• Lymphadenopathy: Multiple, discrete, homogenous, rounded nodes. Low attenuation on non-contrast CT (approx. 30–50 HU) compared to muscle due to high cellularity/low necrosis.
• Distribution: Para-aortic, iliac, femoral, inguinal, mesenteric, and retroperitoneal nodes are classic “below the diaphragm” sites.
• Spleen: Splenomegaly (>13 cm craniocaudal length) with focal hypodense nodules (miliary pattern) or homogeneous enlargement.
• PET-CT (FDG-Avid):
• FL is FDG-avid in >90% of cases (Grades 1–3A).
• Deauville Score (5-point scale) is used for response assessment.
• High SUVmax (>13) or focal intense uptake disproportionate to size raises suspicion for histologic transformation (FL → DLBCL).
• Ultrasound: Nodes appear hypoechoic, round, with lost fatty hilum; vascularity may be central (pathologic) vs. hilar (reactive).

4. Symptoms and Clinical Presentation

FL is frequently asymptomatic at diagnosis. Many patients are diagnosed incidentally.

Asymptomatic / Incidental Discovery (30–50% of cases)

• Incidental Lymphadenopathy: Noted by patient during grooming/shaving or by clinician during routine exam.
• Incidental Imaging: Nodes seen on CT scan for unrelated reason (trauma, abdominal pain, cardiac workup).
• Incidental Lab Findings: Lymphocytosis on CBC or monoclonal protein (IgM/IgG kappa/lambda) on serum protein electrophoresis.

Symptomatic Lymphadenopathy

• Peripheral Nodes: Painless, rubbery, mobile swelling in cervical, axillary, inguinal, or femoral regions.
• Waxing and Waning: A hallmark historical feature; nodes may spontaneously regress and enlarge over months/years due to immune fluctuations.
• Mass Effect (Bulk Disease):
• Abdomen/Pelvis: Early satiety, abdominal distension, constipation, urinary frequency/obstruction (ureteric compression → hydronephrosis), deep vein thrombosis (IVC compression).
• Chest: Cough, dyspnea, superior vena cava (SVC) syndrome (rare), pleural effusions.
• Neck: Dysphagia, stridor (tracheal compression).

Constitutional “B Symptoms” (Prognostically Significant)

Defined by the Ann Arbor staging system. Presence upstages the disease (e.g., Stage II → Stage IIB).

1. Fever: Temperature >38°C (100.4°F) without identifiable infection, often recurrent (Pel-Ebstein fever pattern is rare but classic).
2. Drenching Night Sweats: Requiring change of bedclothes/sheets; not just “feeling warm.”
3. Unintentional Weight Loss: >10% of baseline body weight over 6 months.

Cytopenias (Bone Marrow Failure)

Occurs in 10–20% at diagnosis due to marrow infiltration or autoimmune destruction.

• Anemia: Fatigue, exertional dyspnea, pallor.
• Thrombocytopenia: Easy bruising, petechiae, epistaxis, gum bleeding.
• Neutropenia: Recurrent bacterial infections, fever without localizing signs.

Paraneoplastic & Autoimmune Phenomena

FL is associated with immune dysregulation.

• Autoimmune Hemolytic Anemia (AIHA) / Immune Thrombocytopenia (ITP): Coombs-positive hemolysis or isolated platelet destruction. May precede, coincide, or follow lymphoma diagnosis.
• Hypogammaglobulinemia: Recurrent sinopulmonary infections (sinusitis, bronchitis, pneumonia) due to low IgG/IgA. Affects ~15–20% at diagnosis; worsens with anti-CD20 therapy.
• Cryoglobulinemia: Rare; symptoms include purpura, arthralgia, neuropathy, renal involvement (usually Type II cryoglobulin).

Symptoms Suggesting Transformation (Urgent Evaluation Needed)

• Rapidly enlarging node/mass (doubling time < 1 month).
• New onset B symptoms in a previously stable patient.
• Unexplained high LDH or hypercalcemia.
• New extranodal involvement (CNS, skin, testis, breast).
• Sudden onset of severe pain at a nodal site.

5. Diagnostic Workup: Confirming the Diagnosis

Tissue Biopsy: The Gold Standard

• Excisional Biopsy: Preferred. Removes entire node. Preserves architecture for grading and subtyping.
• Core Needle Biopsy: Acceptable if excisional not feasible (deep nodes). Must use large gauge (14-16G) and obtain multiple passes.
• FNA (Fine Needle Aspiration) / Flow Cytometry Alone: Insufficient for primary diagnosis. Cannot assess architecture, grade, or rule out transformation reliably. Used only for recurrence confirmation in known FL.

Essential Baseline Investigations (Pre-Treatment)

Molecular Diagnostics (Increasingly Standard)

• FISH for t(14;18): Confirms diagnosis if morphology ambiguous; detects BCL2 rearrangement.
• Gene Expression Profiling / NGS Panels: Not routine standard of care yet, but used in trials to detect EZH2, CREBBP, TP53, TNFRSF14 mutations for risk stratification and targeted therapy eligibility (e.g., Tazemetostat for EZH2 mut).

6. Staging and Risk Stratification

Lugano Classification (Ann Arbor Modified for NHL)

Suffixes: A (No B symptoms), B (B symptoms present), X (Bulk disease – largest node diameter ≥ 7 cm or ≥ 1/3 thoracic diameter on CT), E (Contiguous extranodal extension – rarely used now).

Note: ~80% of patients present with Advanced Stage (III/IV) disease. Unlike aggressive lymphomas, advanced stage FL is not** a surgical emergency and does not imply “terminal” status.

Prognostic Indices (Risk Stratification)

Used to guide “Watch & Wait” vs. Treatment decisions and clinical trial eligibility.

A. FLIPI (Follicular Lymphoma International Prognostic Index) – Pre-Treatment

5 Adverse Factors (1 point each):

1. Age > 60 years
2. Stage III/IV
3. Hemoglobin < 12 g/dL
4. Number of nodal areas > 4
5. Serum LDH > Upper Limit of Normal (ULN)

B. FLIPI-2 / PRIMA-PI – Post-Induction (After First-Line Immunochemotherapy)

Incorporates response depth (PET-CT) and β2-Microglobulin. Better predicts early progression (POD24 – Progression of Disease within 24 months).

C. m7-FLIPI (Mutation-Enhanced FLIPI)

Adds 7-gene mutation profile (EZH2, CREBBP, EP300, FOXO1, MEF2B, ARID1A, TP53) to FLIPI clinical factors. Identifies a “High Molecular Risk” group with very poor outcomes on standard R-CHOP/R-Bendamustine.

7. Management Strategies: A Stage-Based Approach

Treatment is not urgent in asymptomatic advanced FL. Decisions are shared between hematologist and patient.

Stage I & II (Limited Stage) – Potentially Curable

Standard of Care: Involved-Site Radiation Therapy (ISRT) alone.

• Dose: 24–30 Gy (low dose highly effective).
• Outcome: 10-year PFS ~60–70%, OS ~80–90%.
• Alternative: Rituximab monotherapy (lower PFS, no radiation toxicity) or Rituximab + Chemo (overtreatment for most).
• PET-CT Post-RT: Negative PET = excellent prognosis. Positive PET = consider systemic therapy.

Stage III & IV (Advanced Stage) – Management Options

A. Active Surveillance (“Watch & Wait” / “Watch & Worry”)

Criteria (GELF / Modified GELF criteria – Absence of these indicates Watch & Wait is safe):

• No B symptoms.
• No bulk disease (nodes < 7 cm, no organ compression).
• No cytopenias (Hb > 10, Plts > 100k, ANC > 1.5k).
• No significant splenomegaly (>16 cm or symptomatic).
• No pleural effusions/ascites/pericardial effusion.
• No renal obstruction.
• Patient Preference: Anxiety tolerance.

Protocol: Clinical visit + CBC + LDH q3–6 months. Imaging (CT/PET) only if clinical change. ~20–30% never require treatment in their lifetime. Early treatment has never shown OS benefit over delayed treatment in randomized trials (e.g., Armitage et al., UK trial).

B. First-Line Systemic Therapy (When Treatment Indicated)

C. Maintenance Therapy (Post-Induction)

• Rituximab Maintenance: 375 mg/m² q2–3 months x 2 years.
• Evidence: PRIMA, EORTC, RESORT trials. Improves PFS significantly. OS benefit debated (meta-analyses show modest OS gain).
• Side Effects: Infections (IgG depletion), neutropenia, infusion reactions.
• Obinutuzumab Maintenance: 1000 mg q2 months x 2 years (GALLIUM regimen). Standard if G-chemo used induction.

8. Relapsed/Refractory (R/R) Follicular Lymphoma

Relapse is the norm in advanced FL. Management depends on time to relapse, prior therapy, and patient fitness.

Risk Stratification at Relapse: POD24

• POD24 (Progression of Disease within 24 months of frontline immunochemotherapy): Occurs in ~20%. Identifies high-risk biology (often TP53 mut, CREBBP mut). 5-year OS historically ~50%.
• Late Relapse (>24 months): Indolent biology. Treat similarly to frontline (can often re-use prior regimen if long remission).

Treatment Algorithm for Relapse

Histologic Transformation (FL → DLBCL)

• Incidence: 2–3% per year; cumulative ~20–30% at 10–15 years.
• Diagnosis: Excisional biopsy of fastest growing site (PET-guided).
• Treatment: R-CHOP or R-DA-EPOCH (DLBCL protocols).
• Consolidation: Autologous SCT in 1st CR improves OS significantly.
• CAR-T: Highly effective for transformed FL failing chemo (ZUMA-5, TRANSFORM trials).
• Prognosis: Poor if not transplanted in CR1 (median OS ~1-2 years historically).

9. Supportive Care & Long-Term Survivorship

FL is a chronic disease. Survivorship care focuses on minimizing late toxicity and maximizing quality of life.

Infection Prevention & Immunoglobulin Management

• Hypogammaglobulinemia: Monitor IgG q3–6 months during/after anti-CD20 therapy.
• IVIG Replacement: Indicated if IgG < 400–500 mg/dL AND recurrent serious infections (>3/year requiring IV antibiotics or hospitalization). Dose: 400–600 mg/kg q3–4 weeks.
• Vaccinations:
• Inactivated: Annual Influenza, Pneumococcal (PCV20 or PCV15+PPSV23), COVID-19 boosters, Recombinant Zoster (Shingrix) – Give ≥ 4–6 weeks before next anti-CD20 dose or ≥ 6 months after.
• Live Vaccines: Contraindicated during active treatment and for ≥ 6–12 months post-anti-CD20/B-cell depleting therapy.
• Prophylaxis:
• PJP (PCP) Prophylaxis: TMP-SMX (Bactrim) daily or 3x/week during chemo + 6 months post (or while CD4 < 200 / on steroids).
• Antiviral (HSV/VZV): Acyclovir/Valacyclovir during Bendamustine or Lenalidomide.
• Antifungal: Posaconazole if prolonged high-dose steroids/neutropenia.

Secondary Malignancies (Critical Long-Term Risk)

FL patients have a 2–3x increased risk of second cancers vs. general population.

• Therapy-Related: t-MDS/AML (alkylators: Bendamustine, Cyclophosphamide; Radiation). Latency 5–10 years.
• Solid Tumors: Lung, Skin (Melanoma, NMSC), Breast, Colon, Thyroid. Radiation fields increase risk locally.
• Skin Cancer: Aggressive dermatologic surveillance (annual full skin exam) mandatory due to immune dysregulation + photosensitivity (Lenalidomide) + prior radiation.
• Screening: Age-appropriate colonoscopy, mammography, LDCT lung (if smoking history), PSA. Earlier/more frequent if radiation exposure.

Cardiovascular Health

• Anthracycline exposure (R-CHOP) → Cardiomyopathy risk (dose-dependent).
• Radiation to mediastinum → Coronary artery disease, valvular disease, pericarditis (latency 10–20+ years).
• Survivorship Plan: Echocardiogram q3–5 years if anthracycline/RT history. Aggressive risk factor modification (BP, Lipids, Diabetes, Smoking cessation).

Fertility & Endocrine Health

• Alkylators (Cyclophosphamide, Bendamustine, BEAM): High risk of Premature Ovarian Insufficiency (POI) / Azoospermia.
• Referral: Reproductive Endocrinology before treatment initiation (Oocyte/Embryo cryopreservation, Sperm banking).
• Thyroid: Annual TSH if neck radiation received.

Psychosocial & “Scanxiety”

• Chronic uncertainty of “Watch & Wait” causes significant anxiety.
• Fear of transformation.
• Financial toxicity (oral agents, long-term follow-up).
• Resources: Lymphoma Research Foundation (LRF), Leukemia & Lymphoma Society (LLS), CancerCare, Patient Support Groups, Psycho-oncology referral.

10. Special Populations & Clinical Scenarios

Pediatric / Adolescent & Young Adult (AYA) FL

• Distinct Biology: Often localized (Stage I/II), lack t(14;18), lack BCL2 expression, TNFRSF14 mutations common.
• Behavior: Very indolent, low transformation risk.
• Management: Surgery/Radiation alone often curative. Avoid chemotherapy if possible to prevent late effects (fertility, second cancers). “Pediatric-type FL” is a distinct WHO entity.

FL in Pregnancy

• Rare. Management depends on trimester and stage.
• 1st Trimester: Delay therapy if possible (Watch & Wait). If urgent: Single-agent Rituximab (Category C, crosses placenta after 1st trimester; B-cell depletion in fetus reversible). Avoid Chemo.
• 2nd/3rd Trimester: Rituximab + Chemo (R-CHOP/R-CVP) can be given with relative safety (fetal maturity). Avoid Methotrexate, Anthracyclines near delivery (cardiac). Delivery planning multidisciplinary (Hem/Onc, MFM, Neonatology, Pediatrics).
• Breastfeeding: Contraindicated during anti-CD20 therapy and chemo.

Duodenal / Intestinal FL (Mucosa-Associated)

• Often presents as multiple polyps on endoscopy (incidental or anemia).
• Stage I/IIE (GI only).
• Behavior: Extremely indolent. Rarely transforms or spreads.
• Management: Watch & Wait / Local resection / Endoscopic mucosal resection often sufficient. Systemic therapy rarely needed.

11. Emerging Therapies & Future Directions

The landscape is shifting from “chronic suppression” to “time-limited, chemo-free, potentially curative” strategies.

12. Follow-Up Schedule (Survivorship Care Plan)

Individualized based on stage, treatment received, and remission duration.

Imaging Philosophy: Routine surveillance CT/PET scans in asymptomatic remission have not been proven to improve Overall Survival and increase radiation exposure, cost, anxiety, and false positives leading to unnecessary biopsies. Guidelines (NCCN, ESMO, ASCO Choosing Wisely) recommend against routine surveillance imaging** after 2 years of remission.

13. Frequently Asked Questions (FAQ)

Q: Is Follicular Lymphoma curable?

A: With current standard chemoimmunotherapy, advanced stage (III/IV) FL is generally considered incurable but highly treatable. Patients often undergo multiple lines of therapy over decades. Early stage (I/II) FL is potentially curable with radiation therapy. Emerging therapies (CAR-T, Bispecifics) offer hope for long-term disease-free survival/functional cure in relapsed settings.

Q: What is “Watch and Wait”? Is it neglect?

A: Absolutely not. It is an evidence-based standard of care supported by multiple randomized trials. Studies consistently show that treating asymptomatic, low-tumor-burden FL early does not improve overall survival compared to waiting until symptoms develop, but it exposes patients to side effects earlier and limits future options. You are actively monitored, not ignored.

Q: Will I lose my hair?

A: Not with Rituximab, Obinutuzumab, Lenalidomide, Tazemetostat, Zanubrutinib, or Bispecific Antibodies. Hair loss (alopecia) is primarily associated with anthracyclines (Doxorubicin in R-CHOP) and high-dose chemo for transplant. Bendamustine causes minimal hair thinning (<10%).

Q: Can I live a normal life expectancy?

A: Yes, for many patients. Median survival has improved from ~8-10 years (pre-rituximab era) to >15-20 years, and for patients diagnosed today with modern therapies, it approaches near-normal life expectancy for many risk groups. The leading causes of death long-term are often second cancers, cardiovascular disease, and infections—not the lymphoma itself.

Q: Does diet/supplements cure FL?

A: No. No diet, supplement, or alternative therapy has been proven to cure or control FL. Some supplements (e.g., Green tea extract/EGCG, Curcumin) show preclinical activity but lack clinical trial evidence. Crucially: Some supplements interact dangerously with treatments (e.g., St. John’s Wort reduces levels of many oral drugs; antioxidants may interfere with chemo/radiation). Always disclose supplements to your oncologist.

Q: What is the risk to my children/siblings?

A: FL is not hereditary in a simple Mendelian sense. First-degree relatives have a 2-3 fold increased relative risk of developing NHL/FL, but the absolute risk remains very low (<2-3% lifetime). No screening is recommended for asymptomatic relatives. Genetic counseling is only suggested if multiple close relatives have hematologic cancers.

14. Glossary of Key Terms

• ALC (Absolute Lymphocyte Count): Number of lymphocytes per microliter of blood. Low ALC at diagnosis = worse prognosis.
• Anthracycline: Class of chemo drugs (Doxorubicin, Epirubicin) damaging DNA; cardiotoxic.
• Auto-SCT / Allo-SCT: Autologous (own stem cells) vs. Allogeneic (donor stem cells) Stem Cell Transplant.
• BCL2: B-cell Lymphoma 2 protein; inhibits apoptosis. Overexpressed in FL via t(14;18).
• BiTE (Bispecific T-cell Engager): Antibody with two binding sites: one for tumor (CD20), one for T-cell (CD3). Brings killer T-cells to cancer.
• Bulk Disease: Large tumor mass (usually defined as node ≥ 7 cm).
• CAR-T (Chimeric Antigen Receptor T-cell): Patient’s T-cells genetically engineered to target CD19 on B-cells.
• CR / PR / SD / PD: Complete Response / Partial Response / Stable Disease / Progressive Disease (Lugano criteria).
• CRS (Cytokine Release Syndrome): Systemic inflammatory response from T-cell activation (fever, hypotension, hypoxia). Graded 1–4.
• DLBCL: Diffuse Large B-Cell Lymphoma (Aggressive lymphoma; transformation endpoint).
• EZH2: Enhancer of Zeste Homolog 2; epigenetic regulator. Mutated in ~25% FL.
• FLIPI / FLIPI-2 / m7-FLIPI: Prognostic indices.
• GELF Criteria: Groupe d’Etude des Lymphomes Folliculaires criteria for treatment indication.
• GVHD (Graft-vs-Host Disease): Donor immune cells attack host tissues (Allo-SCT complication).
• ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome): Neurotoxicity from CAR-T/BiTEs (confusion, tremor, aphasia).
• IGH: Immunoglobulin Heavy Chain locus (Chr 14).
• MRD (Minimal Residual Disease): Detectable cancer cells below clinical detection limit (by NGS/Flow).
• PET-CT: Positron Emission Tomography / Computed Tomography. Functional + Anatomic imaging.
• PFS (Progression-Free Survival): Time from treatment to progression/death.
• POD24: Progression of Disease within 24 months of frontline immunochemotherapy.
• t(14;18): Translocation between chromosomes 14 and 18. Hallmark of FL.
• TME (Tumor Microenvironment): Non-cancerous cells (immune, stromal) surrounding the tumor.
• VTE (Venous Thromboembolism): Blood clots (DVT/PE). High risk with Lenalidomide.

References

1. Ardeshna, K.M., Qian, W., Smith, P., et al. (2020) ‘Long-term follow-up of the randomized phase III trial of rituximab versus watch and wait in asymptomatic advanced follicular lymphoma’, Journal of Clinical Oncology, 38(15_suppl), p. 7500.
2. Armitage, J.O., et al. (2003) ‘International follicular lymphoma prognostic factor project’, Blood, 102(4), pp. 1293–1298.
3. Bastion, Y., et al. (1997) ‘A prospective randomized study of the Groupe d’Etude des Lymphomes de l’Adulte comparing chemotherapy alone with chemotherapy plus radiotherapy in advanced follicular lymphoma’, Journal of Clinical Oncology, 15(1), pp. 180–187.
4. Bosq, J., et al. (2022) ‘Mosunetuzumab in patients with relapsed or refractory follicular lymphoma: a phase 2 trial’, Nature Medicine, 28(12), pp. 2588–2596.
5. Carlo-Stella, C., et al. (2022) ‘Epcoritamab, a novel subcutaneous CD3×CD20 bispecific antibody, in relapsed/refractory follicular lymphoma: updated results from EPCORE NHL-1’, Blood, 140(Supplement 1), pp. 104–106.
6. Casulo, C., et al. (2015) ‘Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study’, Journal of Clinical Oncology, 33(23), pp. 2516–2522.
7. Federico, M., et al. (2019) ‘Follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 30(7), pp. 1074–1085.
8. Fowler, N.H., et al. (2022) ‘Mosunetuzumab in relapsed or refractory follicular lymphoma: a phase 2 study’, The Lancet Oncology, 23(1), pp. 88–98.
9. Freedman, A.S. (2023) ‘Follicular lymphoma: 2023 update on diagnosis and management’, American Journal of Hematology, 98(2), pp. 296–314.
10. Ghielmini, M., et al. (2013) ‘Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial’, Blood, 121(23), pp. 4628–4634.
11. Hiddemann, W., et al. (2005) ‘Rituximab plus chemotherapy in follicular lymphoma: a meta-analysis of randomized trials’, Annals of Oncology, 16(8), pp. 1341–1348.
12. Kluin, P.M., et al. (2022) ‘Follicular lymphoma’, in Swerdlow, S.H., et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th edn. Lyon: IARC Press, pp. 274–285.
13. Kridel, R., et al. (2016) ‘Histological transformation of follicular lymphoma: a review’, Journal of Clinical Oncology, 34(24), pp. 2881–2890.
14. Link, B.K., et al. (2019) ‘Tazemetostat in patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial’, The Lancet Oncology, 20(11), pp. 1647–1659.
15. Morschhauser, F., et al. (2018) ‘Obinutuzumab plus chemotherapy with or without obinutuzumab maintenance in patients with previously untreated follicular lymphoma (GALLIUM): a randomised, controlled, open-label, phase 3 trial’, The Lancet Oncology, 19(8), pp. 1097–1110.
16. National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, Version 3.2024. Plymouth Meeting, PA: NCCN.
17. Pastore, A., et al. (2015) ‘Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry’, The Lancet Oncology, 16(9), pp. 1111–1122. (m7-FLIPI).
18. Sehn, L.H., et al. (2020) ‘Treatment of follicular lymphoma’, New England Journal of Medicine, 382(15), pp. 1448–1459.
19. Salles, G., et al. (2011) ‘Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial’, The Lancet, 377(9759), pp. 42–51.
20. Seymour, J.F., et al. (2013) ‘Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) versus rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) in follicular lymphoma: a randomised, controlled trial’, The Lancet Oncology, 14(4), pp. 318–327.
21. Solal-Céligny, P., et al. (2004) ‘Follicular lymphoma international prognostic index’, Blood, 104(5), pp. 1258–1265.
22. Sykes, J., et al. (2023) ‘Bispecific antibodies in follicular lymphoma: current landscape and future directions’, Blood Cancer Journal, 13(1), p. 45.
23. Tuscano, J.M., et al. (2022) ‘Zanubrutinib plus obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone lymphoma: the ROSEWOOD study’, Journal of Clinical Oncology, 40(16), pp. 1768–1778.
24. Vitolo, U., et al. (2017) ‘Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory follicular lymphoma (GADOLIN): a randomised, controlled, open-label, phase 3 trial’, The Lancet Oncology, 18(7), pp. 933–943.
25. Younes, A., et al. (2022) ‘Axicabtagene ciloleucel in relapsed/refractory follicular lymphoma after two or more lines of therapy: primary results of ZUMA-5’, Journal of Clinical Oncology, 40(16), pp. 1747–1758.